Login to Your Account

Ascletis becomes first biopharma to file under new HKEX listing rules

By Elise Mak
Staff Writer

Wednesday, May 16, 2018

HONG KONG – Hangzhou, China-based Ascletis Pharma Inc. became the first pre-revenue biotech startup to seek public listing in Hong Kong last week. The company plans to use the proceeds to advance its two hepatitis C drug candidates into commercialization in China.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription